Lin et al. reported that YAP promotes resistance to RAF- and MEK-inhibitors potentially through upregulation of the pro-survival gene BCL-XL and that combined YAP and RAF or MEK inhibition leads to synthetic lethality in BRAF- and RAS-mutant tumor types [88]. Here, YAP1 is linked to neoplasm.